TAK-632
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406295

CAS#: 1228591-30-7

Description: TAK-632 is a potent pan-RAF inhibitor with favorable in vitro activity (BRAF(V600E) IC50, 2.4 nM; BRAF(wt), 8.3 nM; CRAF, 1.4 nM; pMEK (A375) IC50, 12 nM; pMEK (HMVII), 49 nM; V/B ratio. In addition, TAK-632 was shown preclinically to be a selective kinase inhibitor targeting pan-RAF kinase activity by testing against a panel of kinases. In both A375 (BRAFV600E) and HMVII (NRASQ61K) xenograft models in rats, TAK-632 demonstrated regressive antitumor efficacy by twice daily, 14-day repetitive administration without significant body weight loss


Chemical Structure

img
TAK-632
CAS# 1228591-30-7

Theoretical Analysis

MedKoo Cat#: 406295
Name: TAK-632
CAS#: 1228591-30-7
Chemical Formula: C27H18F4N4O3S
Exact Mass: 554.10
Molecular Weight: 554.510
Elemental Analysis: C, 58.48; H, 3.27; F, 13.70; N, 10.10; O, 8.66; S, 5.78

Price and Availability

Size Price Availability Quantity
10mg USD 150 Ready to Ship
25mg USD 250 Ready to ship
50mg USD 450 Ready to ship
100mg USD 750 Ready to ship
200mg USD 1350 Ready to ship
500mg USD 2950 2 Weeks
1g USD 4450 2 Weeks
Bulk inquiry

Synonym: TAK632, TAK 632, TAK-632

IUPAC/Chemical Name: N-(7-cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide

InChi Key: OJFKUJDRGJSAQB-UHFFFAOYSA-N

InChi Code: InChI=1S/C27H18F4N4O3S/c28-19-7-6-17(12-21(19)33-23(36)11-14-2-1-3-16(10-14)27(29,30)31)38-22-9-8-20-24(18(22)13-32)39-26(34-20)35-25(37)15-4-5-15/h1-3,6-10,12,15H,4-5,11H2,(H,33,36)(H,34,35,37)

SMILES Code: O=C(C1CC1)NC(S2)=NC3=C2C(C#N)=C(OC4=CC(NC(CC5=CC=CC(C(F)(F)F)=C5)=O)=C(F)C=C4)C=C3

Appearance: White solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Product Data:
Biological target: TAK-632 is a potent pan-RAF inhibitor with IC50 of 1.4, 2.4 and 8.3 nM for CRAF, BRAFV600E, BRAFWT, respectively.
In vitro activity: The selective pan-RAF inhibitor TAK-632 suppresses RAF activity in BRAF wild-type cells with minimal RAF paradoxical activation. Using RNAi and TAK-632 in preclinical models reveals that the MAPK pathway of NRAS-mutated melanoma cells is highly dependent on RAF. TAK-632 induces RAF dimerization but inhibits the kinase activity of the RAF dimer, probably because of its slow dissociation from RAF. As a result, TAK-632 demonstrates potent antiproliferative effects both on NRAS-mutated melanoma cells and BRAF-mutated melanoma cells with acquired resistance to BRAF inhibitors through NRAS mutation or BRAF truncation. Furthermore, the combination of TAK-632 and the MAPK kinase (MEK) inhibitor TAK-733 exhibits synergistic antiproliferative effects on these cells. The unique features of TAK-632 as a pan-RAF inhibitor provide rationale for its further investigation in NRAS-mutated melanoma and a subset of BRAF-mutated melanomas refractory to BRAF inhibitors. Reference: Cancer Res. 2013 Dec 1;73(23):7043-55. http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=24121489
In vivo activity: In vivo efficacy of TAK-632 (8B) was evaluated using an SD formulation in a human melanoma A375 (BRAFV600E) xenograft model in F344 nude rats. Reflecting the potent in vitro pMEK inhibition, oral single administration of 8B inhibited pERK in tumors at 8 h after its administration over a dose range of 1.9–24.1 mg/kg (Figure 7). In particular, 9.7–24.1 mg/kg dosing with 8B strongly inhibited pERK levels to 11% of the control. The antitumor efficacy of 8B was examined by administration twice daily for 14 days in an A375 xenograft model in rats (Figure 8). Compound 8B exhibited dose-dependent antitumor efficacy without severe body weight reduction over a dose range of 3.9–24.1 mg/kg. Significant tumor regression was observed at 9.7 mg/kg and 24.1 mg/kg (T/C = −2.1% and −12.1%, respectively). Next, antitumor effects of 8B in a human melanoma HMVII (NRASQ61K/BRAFG469V) xenograft model were evaluated in rats (Figure 9). In this study, 8B was orally administered as an SD formulation and suppressed the growth of HMVII tumors with T/C values of 52%, 26%, and 0% at doses of 3.9 mg/kg, 9.7 mg/kg, and 24.1 mg/kg, respectively. This antitumor efficacy was dose-dependent and significant (p < 0.025) compared with that of the vehicle control at all three doses. In this model, the HMVII tumor induced cancer cachexia and resulted in approximately 6% body weight loss in the vehicle control group over the 14-day administration period (body weight change: −8.6 g for the vehicle and +16.5 g for nontumor bearing). Interestingly, dose-dependent recovery of body weight loss was observed. In particular, the group at 24.1 mg/kg showed no signs of body weight loss (body weight change: +28.4 g). Reference: J Med Chem. 2013 Aug 22;56(16):6478-94. https://doi.org/10.1021/jm400778d

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 30.0 54.10
Ethanol 2.0 3.60

Preparing Stock Solutions

The following data is based on the product molecular weight 554.510000000000000000000000000000 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol: 1. Okaniwa M, Hirose M, Arita T, Yabuki M, Nakamura A, Takagi T, Kawamoto T, Uchiyama N, Sumita A, Tsutsumi S, Tottori T, Inui Y, Sang BC, Yano J, Aertgeerts K, Yoshida S, Ishikawa T. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. J Med Chem. 2013 Aug 22;56(16):6478-94. doi: 10.1021/jm400778d. Epub 2013 Aug 1. PMID: 23906342. 2. Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E, Galvin K, Okaniwa M, Ishikawa T, Yoshida S. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Res. 2013 Dec 1;73(23):7043-55. doi: 10.1158/0008-5472.CAN-13-1825. Epub 2013 Oct 11. PMID: 24121489.
In vivo protocol: 1. Okaniwa M, Hirose M, Arita T, Yabuki M, Nakamura A, Takagi T, Kawamoto T, Uchiyama N, Sumita A, Tsutsumi S, Tottori T, Inui Y, Sang BC, Yano J, Aertgeerts K, Yoshida S, Ishikawa T. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. J Med Chem. 2013 Aug 22;56(16):6478-94. doi: 10.1021/jm400778d. Epub 2013 Aug 1. PMID: 23906342.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E, Galvin K, Okaniwa M, Ishikawa T, Yoshida S. Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma. Cancer Res. 2013 Dec 1;73(23):7043-55. doi: 10.1158/0008-5472.CAN-13-1825. Epub 2013 Oct 11. PubMed PMID: 24121489. 2: Okaniwa M, Hirose M, Arita T, Yabuki M, Nakamura A, Takagi T, Kawamoto T, Uchiyama N, Sumita A, Tsutsumi S, Tottori T, Inui Y, Sang BC, Yano J, Aertgeerts K, Yoshida S, Ishikawa T. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. J Med Chem. 2013 Aug 22;56(16):6478-94. doi: 10.1021/jm400778d. Epub 2013 Aug 1. PubMed PMID: 23906342. 3: Sung SH, Jeon SW, Son HS, Kim SK, Jung MK, Cho CM, Tak WY, Kweon YO. Factors predictive of risk for complications in patients with oesophageal foreign bodies. Dig Liver Dis. 2011 Aug;43(8):632-5. doi: 10.1016/j.dld.2011.02.018. Epub 2011 Apr 3. PubMed PMID: 21466978. 4: Biró E, Nieuwland R, Tak PP, Pronk LM, Schaap MC, Sturk A, Hack CE. Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals. Ann Rheum Dis. 2007 Aug;66(8):1085-92. Epub 2007 Jan 29. PubMed PMID: 17261534; PubMed Central PMCID: PMC1954699.